Compared with the same treatment given entirely in the adjuvant setting, this application improves event-free survival in resectable stage III–IV melanoma patients.
First-line pembrolizumab plus chemoradiotherapy shows favourable trend to improved EFS in locally advanced head and neck squamous cell carcinoma.
Improvement seen in progression-free survival and ORR by the selective KRAS G12C inhibitor over docetaxel in previously treated KRAS G12C-mutated NSCLC.
Overall survival seems numerically longer with abemaciclib + NSAI in post-menopausal patients with HR-positive / HER2-negative advanced breast cancer.
Patients with TNBC with over 40% Tumour Infiltrating Lymphocytes in their tumour, respond well on neoadjuvant immune checkpoint blockade.
Cabozantinib/ nivolumab/ipilimumab improves progression-free survival versus dual nivolumab/ipilimumab in untreated advanced renal cell carcinoma.
Phase 3 Checkmate 914 trial showed that the adjuvant treatment does not improve survival for stage II–III localised RCC, which has high post-nephrectomy risk.
Second-line treatment with TIL improves PFS compared with ipilimumab in patients with advanced, non-resectable stage III–IV melanoma.
Addition of enzalutamide to AAP does not improve overall survival of metastatic hormone-sensitive prostate cancer patients, STAMPEDE trial results show.
Addition of maintenance olaparib to bevacizumab provides clinically meaningful overall survival benefit in patients who are HRD-positive.
Increasing exposure to 2.5 µm particulate matter increases the risk of non-small cell lung cancer in non-smoking individuals with EGFR mutations.
Final study analysis did not show benefit in advanced hepatocellular carcinoma, but lenvatinib's role as standard first-line treatment in aHCC was supported.
Deep learning from digitalised haematoxylin and eosin-stained whole-tumour slide images outperformed classical Miettinen relapse risks prediction.
Treatment with nivolumab/ipilimumab for 4 weeks achieved a major pathological response in 95% of patients with stage III dMMR colon cancer.
A trial demonstrated a doubling of PFS and a near doubling of overall survival with the VEGF-1, -2, and -3 inhibitor in patients with refractory mCRC.